Medicalgorithmics S A : Partners with US IDTF to Provide Software, AI Driven Analytics, and Monitoring Hardware

October 6, 2023

Medicalgorithmics, SA, a global leader in arrythmia monitoring software and AI-driven analytics, is pleased to announce it entered a definitive agreement to provide a burgeoning independent diagnostic and testing facility (IDTF) based in the southwestern United States with software, AI-driven analytics, and heart monitoring devices.

James Landis, Chief Commercial Officer at Medicalgorithmics, remarked, "We're thrilled to execute our strategy, marking the third partnership in just four months since its announcement. This continues to bolster our collaborative efforts with IDTF entities in the US. Each subsequent agreement aligns us closer to our overarching vision of curating a network of alliances in the cutting-edge cardiac diagnostics space. This not only diversifies our revenue stream from the US but also complements our consistently expanding and multifaceted business footprint beyond American shores."

Pursuing its strategy to become the global leader in arrythmia monitoring software with a diverse client base of IDTFs, hardware manufacturers, hospital systems, and clinical trial sponsors, Medicalgorithmics continues to expand collaborations in the United States, Europe, the Middle East, Asia, and India. The differentiated software platform was developed over the last 18 years and is based on 2.5 billion annotated heartbeats collected from patients around the globe. By incorporating cutting edge algorithms developed by the team of Poland based engineers and programmers, the system is capable of recognizing more arrythmias than competing products in the market. Developed software platform provides healthcare professionals with unparalleled insights, optimize workflows, and substantially curtail the need for manual data assessments by technicians.

Medicalgorithmics is a global medtech company, specialized in AI-enhanced, non-invasive cardiac arrhythmia solutions. Its broad portfolio of products augments patient monitoring, enabling prompt ailment detection, accurate diagnosis, and meticulous health oversight.

As a matter of policy, Medicalgorithmics maintains confidentiality of client and customer names unless specifically requested by the client or required by law.

For further details, kindly reach out to:

Media:

Mariusz Gawrychowski

InnerValue

m.gawrychowski@innervalue.pl

+48 501 520 598

Investors:

Robert Mrozowski

InnerValue

r.mrozowski@innervalue.pl

+48 513 083 322

The publication can be downloaded here:

• October 6, 2023